« Back to Record
Citation APA

Loi, S., Estrada, M. V., Sanchez, V., Sanders, M. M., Cook, R. R., Pilkinton, M. A. L. M., Mallal, S. A., Wang, K., Miller, V. A., Stephens, P. J., Yelensky, R., Dushyanthen, S., Doimi, F. F., Gomez, H., Ryzhov, S. S., Darcy, P. K., Arteaga, C. L., Balko, J. M., Beavis, P. P., Salgado, R., Denkert, C., Savas, P., Combs, S., Rimm, D. D., & Giltnane, J. J. (2016). RAS/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: Therapeutic cooperation between MEK and PD-1/PD-L1 immune checkpoint inhibitors. Clinical cancer research, 22(6), 1499-1509. doi:10.1158/1078-0432.CCR-15-1125


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/231571

Loi, S., Estrada, M. V., Sanchez, V., Sanders, M. M., Cook, R. R., Pilkinton, M. A. L. M., Mallal, S. A., Wang, K., Miller, V. A., Stephens, P. J., Yelensky, R., Dushyanthen, S., Doimi, F. F., Gomez, H., Ryzhov, S. S., Darcy, P. K., Arteaga, C. L., Balko, J. M., Beavis, P. P., Salgado, R., Denkert, C., Savas, P., Combs, S., Rimm, D. D., & Giltnane, J. J. (2016). RAS/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: Therapeutic cooperation between MEK and PD-1/PD-L1 immune checkpoint inhibitors. Clinical cancer research, 22(6), 1499-1509. doi:10.1158/1078-0432.CCR-15-1125